Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius

Executive Summary

Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.


Related Content

Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’
Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market
Cubist Nears Goalpost Of Five Marketed Drugs In 2015
Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius
Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints
Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
Optimer's Early Sales Of Dificid Topping Analyst Projections
Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts